| Literature DB >> 14694058 |
R Rojas-García1, E Gallardo, I de Andrés, N de Luna, C Juarez, P Sánchez, I Illa.
Abstract
Two patients with chronic motor neuropathy, high antiganglioside antibody (AGA) titers, and a declining response to IV immunoglobulins were treated with rituximab at a standard dose. The drug was well tolerated and effectively eliminated peripheral B cells (CD20+), but AGA titers continued significantly high. No clinical improvement was detected during the 1-year follow-up.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14694058 DOI： 10.1212/01.wnl.0000098996.02934.86
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910